The efficacy of ferulic acid in the treatment of dementia (double-blinded study)

The efficacy of ferulic acid in the treatment of dementia (double-blinded study) - EFATD2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022222

Enrollment

100

Registered

2016-05-09

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

The treatment group is taking capsules of Ferulic Acid for 12 months. The placebo group is taking capsules not containing Ferulic acid for 12 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects with mild cognitive impairment are registered from Shimnane University Hospital and public subscripiton. MMSE is from 24 to 28.

Exclusion criteria

Exclusion criteria: metabolic encephalopathy(hypothyroidism),head trauma,malignancy,alcohl abuse, mental disorder,chronic renal failure, chronic heart failure,chronic liver injury and patients treated by major tranquilizer.

Design outcomes

Primary

Measure	Time frame
ADAS-Jcog(pre-treatment and one year follow up)	—

Secondary

Measure	Time frame
Hasegawa Dementia Rating Scale, Mini Mental State Examination, Apathy scale,Self Depression Scale, FAB, ADAS-Jcog, Wechsler Memory Scale Revised, MRI(Default mode network,hippocampal atrophy)	—

Countries

Japan

Contacts

Public ContactHiroaki Oguro

Shimane University Hospital Department of Neurology

oguro@med.shimane-u.ac.jp0853232111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026